Bristol-Myers Squibb Company (BMY) and AstraZeneca (AZN.L,AZN) announced that the U.S. FDA has granted a Priority Review designation for the Biologics License Application for metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy.
The FDA grants Priority Review to medicines that may provide a treatment option where little or no adequate therapy exists.
Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to research, develop and commercialize select investigational drugs for type 2 diabetes. The expanded Bristol-Myers Squibb/AstraZeneca collaboration covers the co-development and marketing of products in the Amylin Pharmaceuticals portfolio, including, among others, investigational metreleptin.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.